TriangleCIML NK cells for ovarian cancer (NCT06321484)
CIML NK cells for ovarian cancer trial for Platinum-resistant Ovarian Cancer (NCT06321484). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Ovarian cancer usually answers to platinum chemotherapy at first. When it stops answering, the remaining drugs buy months, and most disease sits inside the abdomen, where it seeds the lining and causes fluid to build.
The idea: put trained natural killer cells exactly there.
At Dana-Farber, a patient's own natural killer cells are collected, then exposed overnight to three immune signals, interleukins 12, 15, and 18, which leaves them in a memory-like state: more alert, longer-lived. After chemotherapy makes room, the cells are infused directly into the abdominal cavity, followed by low doses of interleukin-2 under the skin to keep them active.
An early safety study for recurrent, platinum-resistant high-grade ovarian cancer. Rebecca Porter leads it in Boston. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.